References
- Gold MR , Siegel JE , Russell LB , Weinstein MC . Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996
- Brouwer WBF , Rutten FFH , Koopmanschap MA . Costing in economic evaluations. In: Drummond MF , McGuire A , eds. Economic evaluation in health care: merging theory with practice. New York: Oxford University Press; 2001
- Meltzer D . Future costs in medical cost-effectiveness analysis. In: Jones AM , ed. The Elgar companion to health economics.2nd ed.; 2012. Available from: http://www.elgaronline.com [Last accessed on September 2014]
- Drummond MF , Sculpher MJ , Torrance GW , et al. Methods for the economic evaluation of healthcare programmes. 3rd ed. New York: Oxford University Press; 2005
- Rappange DR , van Bacal PHM , van Evel JA , et al. Unrelated medical costs in life-years gained. Should they be included in economic evaluation of healthcare interventions? Pharmacoeconomics 2008;26:815-30
- Meltzer D . Accounting for future costs in medical cost-effectiveness analysis. J Health Econ 1997;16:33-64
- Liljas B , Karlsson GS , Stalhammer NO . On future non-medical costs in economic evaluations. Health Econ 2008;17:579-91
- Nyman JA . More on survival consumption costs in cost-utility analysis. Health Econ 2006;15:319-22
- Johannesson M , Meltzer D , O´Conor RM . Incorporating future costs in medical cost-effectiveness analysis: implications for the cost-effectiveness of the treatment of hypertension. Med Decis Making 1997;17:382-9
- Manns B , Meltzer D , Taub K , Donaldson C . Illustrating the impact of including future costs in economic evaluations: an application to end-stage renal diseases care. Health Econ 2003;12:949-58
- Grime DT , Bernard LM , Dunn ES , et al. Cost-effectiveness analysis of therapies for chronic kidney patients on dialysis: a case for excluding dialysis costs. Pharmacoeconomics 2012;30:981-9
- Kruse M , Sorensen J , Gyrd-Hansen D . Future costs in cost-effectiveness analysis: an empirical assessment. Eur J Health Econ 2012;39:10-16
- Meltzer D , Egleston B , Stoffel D , Dasbach E . Effect of future costs on cost-effectiveness of medical interventions among young adults: the example of intensive therapy for type 1 diabetes. Med Care 2000;38:679-85
- Viera AJ , Garrett JM . Understanding inter observer agreement: the kappa statistic. Fam Med 2005;37:360-3
- Gandjour A , Lauterbach KW . Does prevention save costs? Considering deferral of the expensive last year of life. J Health Econ 2005;24:715-24
- van Baal PHM , Feenstra TL , Hoogenveen RT , et al. Unrelated medical care in life years gained and the cost utility of primary prevention: in search of a ‘perfect’ cost-utility ratio. Health Econ 2007;16:421-33
- Lee RH . Future costs in cost-effectiveness analysis. J Health Econ 2008;27:809-18
- Nyman JA . Measurement of QALYs and the welfare implications of survivor consumption and leisure forgone. Health Econ 2011;20:56-67
- van Baal PHM , Feenstra TL , Polder JJ , et al. Economic evaluation and the postponement of healthcare cost. Health Econ 2011;20:432-45
- van Baal PHM , Wong A , Slobbe LCJ , et al. Standardizing the inclusion of indirect medical costs in economic evaluations. Pharmacoeconomics 2011;29:175-87
- van Baal P , Meltzer D , Brouwer W . Pharmacoeconomic guidelines should prescribe inclusion of indirect medical costs! A response to Grima et al. Pharmacoeconomics 2013;31:369-73
- Gandjour A , Müller D . Ethical objections against including life-extension costs in cost-effectiveness analysis: a consistent approach. Appl Health Econ Health Policy 2014;12:471-6